<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01234441</url>
  </required_header>
  <id_info>
    <org_study_id>1R01DK084016-01</org_study_id>
    <nct_id>NCT01234441</nct_id>
  </id_info>
  <brief_title>Intra Hemodialytic Oral Protein and Exercise (IHOPE)</brief_title>
  <acronym>IHOPE</acronym>
  <official_title>Intradialytic Protein Supplementation &amp; Exercise Training in Dialysis Patients.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Illinois at Urbana-Champaign</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Illinois at Chicago</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Illinois at Urbana-Champaign</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Chronic kidney disease (CKD) patients receiving hemodialysis treatment (CKD stage 5) suffer
      from a variety of co-morbid diseases, many of which may be mechanistically linked. Protein
      malnutrition, muscle catabolism and wasting are especially common, and these lead to reduced
      muscle strength, declines in physical function, and low levels of physical activity. Physical
      inactivity exacerbates these functional declines, and also promotes cardiovascular disease
      (CVD) and bone disorders. This cycle of disease and disability greatly reduces quality of
      life (QOL) and increases mortality rates in dialysis patients.

      Many factors contribute to the development of these co-morbidities. Chronic inflammation is
      believed to be a cause and a consequence of the protein malnutrition, CVD and bone disorders
      in dialysis patients. In addition, abnormalities in mineral metabolism resulting from the
      deficit in kidney function promote the loss of mineral from bone and the deposition of
      mineral in the vasculature, a process termed vascular calcification (VC). VC is associated
      with a variety of CVD-related disorders, including arterial stiffness, increases in arterial
      wall intima-media thickness (IMT), left ventricular hypertrophy (LVH), and declines in
      cardiac function. As a result of these abnormalities, cardiovascular events are 10 to 30
      times greater in dialysis patients than in age- and sex-matched subjects in the general
      population.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Chronic kidney disease (CKD) patients receiving hemodialysis treatment (CKD stage 5) suffer
      from a variety of co-morbid diseases, many of which may be mechanistically linked. Protein
      malnutrition, muscle catabolism and wasting are especially common, and these lead to reduced
      muscle strength, declines in physical function, and low levels of physical activity. Physical
      inactivity exacerbates these functional declines, and also promotes cardiovascular disease
      (CVD) and bone disorders. This cycle of disease and disability greatly reduces quality of
      life (QOL) and increases mortality rates in dialysis patients.

      Many factors contribute to the development of these co-morbidities. Chronic inflammation is
      believed to be a cause and a consequence of the protein malnutrition, CVD and bone disorders
      in dialysis patients. In addition, abnormalities in mineral metabolism resulting from the
      deficit in kidney function promote the loss of mineral from bone and the deposition of
      mineral in the vasculature, a process termed vascular calcification (VC). VC is associated
      with a variety of CVD-related disorders, including arterial stiffness, increases in arterial
      wall intima-media thickness (IMT), left ventricular hypertrophy (LVH), and declines in
      cardiac function. As a result of these abnormalities, cardiovascular events are 10 to 30
      times greater in dialysis patients than in age- and sex-matched subjects in the general
      population.

      A variety of pharmacological therapies are commonly used to help prevent or attenuate the
      progression of CKD co-morbidities; however, morbidity and mortality in this population remain
      extremely high, indicating that additional therapeutic strategies that may improve the health
      and QOL in this population are needed. Recently, the National Kidney Foundation recommended
      that dialysis patients increase their protein intake to 1.2 g/kg/day to help prevent protein
      malnutrition; however, little is known about the efficacy of this recommendation.
      Intradialytic (during dialysis) protein supplementation has been shown to increase serum
      albumin levels11, and also increases amino acid uptake into skeletal muscle, an effect that
      is potentiated by both resistance and endurance exercise. However, the individual and
      combined effects of intradialytic protein supplementation and exercise training on lean mass,
      muscle strength, and physical function is unknown. Furthermore, intradialytic protein
      supplementation and exercise training improve many risk factors associated with CVD and renal
      bone disease (e.g., plasma lipids, inflammatory variables), but their effect on functional
      CVD outcomes (e.g., arterial stiffness, VC, IMT, LVH, myocardial performance) and bone health
      in dialysis patients is unknown.

      The primary objective of the proposed research is to evaluate the efficacy of intradialytic
      oral protein supplementation, with and without concomitant intradialytic endurance exercise
      training (cycling), on physical function, CVD risk, and bone health. We will also examine
      potential mechanisms for these effects, and determine if improvements in these factors lead
      to improvements in QOL. Hemodialysis patients will be randomized to the following groups for
      12 months: 1) usual care/control (CON); 2) intradialytic protein supplementation (PRO); or 3)
      intradialytic protein supplementation + exercise training (PRO+EX).

      Primary Aim #1: Examine the effects of intradialytic oral protein supplementation and
      exercise training on physical function.

      Hypothesis #1: Physical function, as assessed by a shuttle walk test, will improve in PRO+EX
      and PRO, compared to CON, and the magnitude of improvements will be greatest in PRO+EX. In
      secondary analyses, we also will examine the effects of our interventions on other variables
      related to physical function, including lean body mass, muscle strength, and activities of
      daily living (ADL) assessments.

      Primary Aim #2: Examine the effects of intradialytic oral protein supplementation and
      exercise training on CVD risk.

      Hypothesis #2: CVD risk, as assessed by carotid artery stiffness, will improve in PRO+EX and
      PRO, compared to CON, and the magnitude of improvements will be greatest in PRO+EX. In
      secondary analyses, we also will examine the effects of our interventions on other factors
      related to CVD risk, including carotid IMT, myocardial performance, LVH, aortic
      calcification, and epicardial fat levels.

      Primary Aim #3: Examine the effects of intradialytic oral protein supplementation and
      exercise training on bone health as determined by bone mineral density (BMD).

      Hypothesis #3: BMD will be reduced significantly more in CON than in PRO+EX or PRO. We
      anticipate that BMD will remain stable in PRO+EX or PRO. Because the exercise is not bone
      loading (i.e., invoking ground or joint reaction forces), we do not expect additive effects
      of PRO+EX on BMD.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>December 2010</start_date>
  <completion_date type="Anticipated">December 2016</completion_date>
  <primary_completion_date type="Anticipated">February 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Examine the effects of intradialytic oral protein supplementation and exercise training on physical function.</measure>
    <time_frame>12 months</time_frame>
    <description>Physical function, as assessed by a shuttle walk test, will improve in PRO+EX and PRO, compared to CON, and the magnitude of improvements will be greatest in PRO+EX. In secondary analyses, we also will examine the effects of our interventions on other variables related to physical function, including lean body mass, muscle strength, and activities of daily living (ADL) assessments.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Examine the effects of intradialytic oral protein supplementation and exercise training on CVD risk.</measure>
    <time_frame>12 months</time_frame>
    <description>CVD risk, as assessed by carotid artery stiffness, will improve in PRO+EX and PRO, compared to CON, and the magnitude of improvements will be greatest in PRO+EX. In secondary analyses, we also will examine the effects of our interventions on other factors related to CVD risk, including carotid IMT, myocardial performance, LVH, aortic calcification, and epicardial fat levels.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Examine the effects of intradialytic oral protein supplementation and exercise training on bone health as determined by bone mineral density (BMD).</measure>
    <time_frame>12 months</time_frame>
    <description>BMD will be reduced significantly more in CON than in PRO+EX or PRO. We anticipate that BMD will remain stable in PRO+EX or PRO. Because the exercise is not bone loading (i.e., invoking ground or joint reaction forces), we do not expect additive effects of PRO+EX on BMD.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Kidney Diseases</condition>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>This group of patients will receive a non-nutritive beverage, and no exercise.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Protein</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>This group of patients will ingest 30 grams of a liquid whey protein supplement during the first hour of their dialysis session</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Protein + Exercise</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>This group will ingest 30 grams of a liquid whey protein supplement as well as exercise for 30-45 minutes during their dialysis treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Control</intervention_name>
    <description>A placebo non-nutritive beverage will be administered before dialysis sessions 3 times per week.</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Protein</intervention_name>
    <description>A whey protein beverage will be administered before dialysis sessions 3 times per week.</description>
    <arm_group_label>Protein</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Protein + Exercise</intervention_name>
    <description>A whey protein beverage will be administered before dialysis sessions 3 times per week. Patients will also exercise by stationary bicycle during dialysis sessions 3 times per week.</description>
    <arm_group_label>Protein + Exercise</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Must receive hemodialysis treatment at least 3 days per week.

          -  Must be â‰¥ 30 years of age.

          -  Must be willing to be randomized to the control or intervention groups.

          -  Must be physically able to exercise (e.g., no orthopedic problems that would preclude
             them from cycling during dialysis).

          -  Must receive medical clearance from their primary care physician to participate.

          -  Must be on phosphate binders to control calcium levels.

        Exclusion Criteria:

          -  Persistent hemoglobin levels &lt; 10g/dl.

          -  Weight greater than 300 pounds.

          -  Currently receiving any form of intradialytic protein supplementation (oral, enteral,
             or parenteral) or participating in any form of intradialytic exercise training.

          -  Chronic obstructive pulmonary disease (COPD) and decompensated chronic heart failure
             (CHF).

          -  On dialysis treatment for &lt; 3 months (or enrollment may be postponed).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kenneth R Wilund, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Illinois at Urbana-Champaign</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Illinois at Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Illinois at Urbana-Champaign</name>
      <address>
        <city>Urbana</city>
        <state>Illinois</state>
        <zip>61801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 2, 2010</study_first_submitted>
  <study_first_submitted_qc>November 2, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 4, 2010</study_first_posted>
  <last_update_submitted>December 1, 2015</last_update_submitted>
  <last_update_submitted_qc>December 1, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 3, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Illinois at Urbana-Champaign</investigator_affiliation>
    <investigator_full_name>Kenneth Wilund</investigator_full_name>
    <investigator_title>Prinicipal Responsiple Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

